CYP19A1 Genetic Polymorphisms rs4646 and Osteoporosis in Patients Treated with Aromatase Inhibitor-Based Adjuvant Therapy


Creative Commons License

Mazzuca F., Botticelli A., Mazzotti E., La Torre M., Borro M., Marchetti L., ...Daha Fazla

EURASIAN JOURNAL OF MEDICINE, cilt.48, ss.10-14, 2016 (ESCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 48 Konu: 1
  • Basım Tarihi: 2016
  • Doi Numarası: 10.5152/eurasianjmed.2015.008
  • Dergi Adı: EURASIAN JOURNAL OF MEDICINE
  • Sayfa Sayıları: ss.10-14

Özet

Objective: Third-generation aromatase inhibitors (AI) are potent suppressors of aromatase activity. The aim of this study was to measure the incidence of adverse effects in breast cancer patients treated with AI-based adjuvant therapy and the relationship with the CYP19A1 genotypes.